A potential therapeutic target for the treatment of psoriasis has been identified. Psoriasis is a chronic inflammatory disease of the skin that affects up to a 2% of the population and which has still no cure. The study shows that the TREX2 gene has a relevant role in the inflammatory response that develops during the illness.
There are more and more examples of the ways in which we can benefit from our bacteria. According to new research, this is true for the skin as well. The work has shown that the most common bacteria on human skin secrete a protein which protects us from the reactive oxygen species thought to contribute to several skin diseases. The protein has an equally strong effect on dangerous oxygen species as known antioxidants such as vitamin C and vitamin E.
Dermatophyte infections, the most common kind of fungal infection in the skin, hair, or nails, affect an estimated 25 percent of the world's population and have accounted for 51 million outpatient visits over the last 10 years in the U.S. Now researchers report that fungal skin infections may be commonly misdiagnosed.
The discovery of the shape and binding capability of epidermal cells could explain how skin maintains a barrier even when it is shedding. New research into how epidermal cells form a barrier may explain the paradox of how we can shed them without compromising our skin's integrity. It could also help us to understand what happens when it forms incorrectly, which could lead to conditions like psoriasis and eczema.
The antibody ustekinumab is in use for treatment of psoriasis since 2009. It inhibits the underlying inflammation by neutralizing certain messengers of the immune system. Researchers now shows that one of these messengers could actually be helpful in battling the illness.
Two new studies describe how the inflammatory response to psoriasis can alter levels of several immune system molecules, ultimately increasing a person’s risk of thrombosis, which can include fatal blood clots
A substantial part of people, one in five, undergoing systemic treatment for psoriasis (i.e. pills taken orally, injections or infusions) still have considerable problems with their disease, according to a recent study.
With the aid of thousands of skin biopsies and over a hundred kilograms of skin, researchers have observed how two subgroups of immune cell behave in healthy skin. This functional dichotomy is preserved in the inflammatory diseases psoriasis and vitiligo. The study opens the way for more targeted local treatments for patchy inflammatory skin disorders.
Psoriasis is a lifelong disease that is associated with significant cosmetic and physical disability and puts patients at increased risk for many major medical disorders. A multidisciplinary team of researchers has found that psoriasis patients who developed depression were at a 37 percent greater risk of subsequently developing psoriatic arthritis, compared with psoriasis patients who did not develop depression.
Scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease. The discovery could lead to new and existing medicines that target the molecule being investigated as a way of treating inflammatory diseases, such as psoriasis and inflammatory bowel disease.
The fact that men are overrepresented in psoriasis registers and consume more psoriasis care have long led researchers to believe that the common skin disease disproportionately affects men. A unique study with 5,438 Swedish psoriasis patients now reveals that women have a statistically significant lower incidence of severe psoriasis compared to men.